Abstract

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality, however liver disease due to chronic hepatitis C has emerged as a major comorbidity in this population. We are conducting studies that: (1) evaluate novel therapeutic strategies in the management of hepatitis C virus (HCV)-infected individuals, and (2) identify the signature host response characteristics that predict HCV response to existing treatment and aid in developing better future therapies. This past year, we were able to (1) conduct a novel clinical trial to use interferon free therapy for treatment of HCV genotype 1 infection (2) conduct an interferon and ribavirin free clinical trial for the treatment of HCV in HIV/HCV infected subjects (3) conduct a clinical trial to determine the factors that contribute to HCV clearance using Interferon and ribavirin free therapy. .

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI000390-31
Application #
8946259
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
31
Fiscal Year
2014
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Lee, Yu-Jin; Zhang, Xiaozhen; Vazquez, Estefania et al. (2014) Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFN?R2a. J Interferon Cytokine Res 34:28-34
Kohli, Anita; Shaffer, Ashton; Sherman, Amy et al. (2014) Treatment of hepatitis C: a systematic review. JAMA 312:631-40
Meissner, Eric G; Bon, Dimitra; Prokunina-Olsson, Ludmila et al. (2014) IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 209:1700-4
Osinusi, Anu; Bon, Dimitra; Nelson, Amy et al. (2014) Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. J Med Virol 86:177-85
Meissner, Eric G; Wu, David; Osinusi, Anu et al. (2014) Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124:3352-63
Katsounas, Antonios; Rasimas, Joseph J; Schlaak, Joerg F et al. (2014) Interferon stimulated exonuclease gene 20?kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients. J Med Virol 86:1323-31
Fauci, Anthony S; Marovich, Mary A; Dieffenbach, Carl W et al. (2014) Immunology. Immune activation with HIV vaccines. Science 344:49-51
Kapoor, Rama; Kottilil, Shyam (2014) Strategies to eliminate HBV infection. Future Virol 9:565-585
Sidharthan, Sreetha; Kottilil, Shyam (2014) Mechanisms of alcohol-induced hepatocellular carcinoma. Hepatol Int 8:452-7
Odigie, Madeline; Osinusi, Anu; Barrett, Lisa et al. (2014) Inteleukin-23 promotes interferon-? responsiveness in hepatitis C virus/HIV-coinfected patients. AIDS Res Hum Retroviruses 30:775-82

Showing the most recent 10 out of 50 publications